Chlortetracycline (CTC / Aureomycin)

Chlortetracycline is a tetracycline-class antibiotic that was among the first broad-spectrum antimicrobials developed for veterinary use, with a history extending back to the late 1940s when it was isolated from Streptomyces aureofaciens. This foundational antimicrobial has been used extensively in food animal medicine for treatment, control, and prevention of bacterial diseases in cattle, swine, poultry, and other species. The drug exerts its antibacterial effect by binding to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from entering the acceptor site on the ribosome. This mechanism produces bacteriostatic activity against a wide range of gram-positive and gram-negative bacteria, as well as certain intracellular pathogens including rickettsiae and some protozoa.

The broad spectrum of activity exhibited by chlortetracycline encompasses many bacterial pathogens relevant to livestock production. The drug demonstrates activity against Pasteurella species, Mannheimia haemolytica, Histophilus somni, and other respiratory pathogens affecting cattle and swine. Enteric pathogens including certain Escherichia coli and Salmonella strains may be susceptible. Anaplasmosis, caused by the rickettsial organism Anaplasma marginale, responds particularly well to chlortetracycline therapy. The drug also has activity against Clostridial species, Fusobacterium necrophorum, and various other organisms causing soft tissue infections in livestock.

Chlortetracycline is most commonly administered through medicated feed, making it practical for treating or preventing disease in large groups of animals in modern production settings. The drug is incorporated into feed premixes at specified concentrations and delivered according to label directions or Veterinary Feed Directive requirements. Water medication is also possible with soluble formulations, providing flexibility in administration route. The oral bioavailability of chlortetracycline is affected by concurrent intake of divalent cations including calcium and magnesium, which form insoluble chelates with the drug and reduce absorption. This characteristic has implications for feeding management during treatment.

Regulatory oversight of chlortetracycline has evolved significantly, particularly with the implementation of the Veterinary Feed Directive (VFD) system in the United States in 2017. Feed-use antimicrobials including chlortetracycline now require a VFD from a licensed veterinarian for therapeutic uses, reflecting regulatory emphasis on antimicrobial stewardship and judicious use. The VFD requirement ensures veterinary oversight of antimicrobial use in livestock production while maintaining access to these important therapeutic tools. Growth promotion claims have been removed from chlortetracycline products, limiting approved uses to disease treatment, control, and prevention.

The treatment and control of bovine respiratory disease represents a primary indication for chlortetracycline in cattle operations. The drug is approved for treating and controlling respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica in cattle, addressing one of the most economically significant health challenges in beef and dairy production. Chlortetracycline may be used for metaphylaxis in groups of cattle at high risk for respiratory disease, such as newly arrived feedlot cattle experiencing the stress of transportation and commingling. The drug's availability as a medicated feed makes it practical for treating large numbers of animals simultaneously.

Anaplasmosis prevention and treatment represents a particularly important application for chlortetracycline in endemic areas. Anaplasma marginale, the causative agent of bovine anaplasmosis, is susceptible to tetracycline antibiotics, and chlortetracycline fed at appropriate levels can prevent clinical disease in cattle exposed to infected ticks. Endemic herd treatment programs use continuous low-level chlortetracycline feeding during the transmission season to maintain protective drug concentrations. Animals with clinical anaplasmosis may also be treated with chlortetracycline, though more intensive tetracycline therapy (often with oxytetracycline) may be preferred for acutely ill individuals.

Bacterial enteritis in cattle and swine is another approved indication, with chlortetracycline used for treating and controlling intestinal infections caused by susceptible bacteria. In cattle, bacterial enteritis affecting calves and young stock may respond to chlortetracycline therapy. In swine, the drug is approved for treating bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis, conditions that cause significant economic losses through mortality and reduced growth performance. Water medication with soluble chlortetracycline provides a convenient treatment approach when feed-based administration is not practical.

Foot rot and related soft tissue infections in cattle may be treated with chlortetracycline when caused by susceptible organisms including Fusobacterium necrophorum. While injectable antibiotics may be preferred for individual animal treatment of established foot rot cases, chlortetracycline feed medication can be useful for control programs in herds experiencing endemic foot rot problems. The drug's activity against anaerobic bacteria makes it appropriate for infections involving Fusobacterium and related organisms that thrive in the oxygen-deprived environment of necrotic tissue.

Poultry applications include treatment and control of various bacterial infections. Fowl cholera caused by Pasteurella multocida, a serious and often fatal disease in poultry, may be treated with chlortetracycline medication through feed or water. Infectious synovitis, chronic respiratory disease associated with Mycoplasma gallisepticum, and bacterial enteritis represent additional poultry indications. The practical utility of mass medication through feed or water makes chlortetracycline valuable for treating disease outbreaks in commercial poultry flocks where individual bird treatment would be impractical.

Chlortetracycline dosing through medicated feed follows specific concentrations established for each indication and species. For cattle, therapeutic feed levels typically range from 10 to 22 mg per pound of body weight daily, depending on the condition being treated. Feed formulations are prepared by incorporating chlortetracycline premix into complete feed at concentrations calculated to deliver the appropriate dose based on expected feed consumption. Label directions specify the drug concentration in complete feed (expressed as grams per ton or milligrams per pound of feed) and the duration of feeding for each approved indication.

The Veterinary Feed Directive system governs therapeutic use of chlortetracycline in feed for cattle, swine, and other food animals. Under VFD requirements, a veterinarian must issue a written directive authorizing the feed mill to manufacture and sell medicated feed containing chlortetracycline for a specific client's animals. The VFD specifies the drug, indication, species, number of animals, location, duration of use, withdrawal time, and veterinarian information. VFD antibiotics cannot be purchased over the counter for therapeutic purposes, ensuring veterinary oversight of antimicrobial use decisions.

Water medication with soluble chlortetracycline provides an alternative to feed medication when rapid treatment initiation is needed or when appetite suppression makes feed-based delivery unreliable. The drug is dissolved in drinking water at concentrations calculated to deliver therapeutic doses based on estimated water consumption. Water consumption varies with temperature, diet, and health status, requiring adjustment of medication concentration under different conditions. Hot weather significantly increases water consumption, potentially leading to overdosing if medication concentration is not adjusted accordingly.

Injectable chlortetracycline formulations are less commonly used than oral preparations but are available for situations requiring parenteral administration. These formulations may be administered intramuscularly, though injection site reactions can occur. The pharmacokinetics of injectable chlortetracycline differ from oral administration, with generally higher and more predictable blood levels achieved following injection. Individual animal treatment of acutely ill livestock may employ injectable formulations when mass medication is not appropriate.

Treatment duration varies by indication and severity but typically ranges from 7 to 14 days for most bacterial infections. Anaplasmosis control programs may involve prolonged or continuous feeding during the transmission season, following specific label protocols. Shorter treatment courses may be appropriate for some conditions, while chronic or difficult infections may require extended therapy. Clinical response should guide treatment duration, with continuation until clinical improvement is evident and then for an appropriate period thereafter to ensure complete resolution.

Withdrawal times for chlortetracycline depend on species, formulation, and duration of administration. For cattle, meat withdrawal following feed medication is typically 0 to 2 days for most labeled uses, though specific products may have different requirements. Swine withdrawal is generally 0 to 7 days depending on the specific use and product. Poultry withdrawal varies by indication and bird type. These withdrawal times assume use according to label directions; extra-label use requires extended withdrawal times determined through FARAD consultation. Chlortetracycline is not approved for use in lactating dairy cattle whose milk is intended for human consumption, and specific milk withdrawal periods apply when use in dry cows is contemplated.

Chlortetracycline is generally well-tolerated in food-producing animals when administered according to label directions, though several adverse effects may occur and require consideration during treatment. Gastrointestinal disturbances represent the most common side effects, particularly with oral administration of high doses. Diarrhea, reduced appetite, and changes in fecal consistency may reflect disruption of normal gastrointestinal microflora by the antibiotic's broad-spectrum activity. Ruminants may experience alterations in rumen microbial populations that affect digestive function, though this is generally less problematic with feed-based chlortetracycline than with parenteral tetracycline administration.

Photosensitization is a recognized adverse effect of tetracycline antibiotics, including chlortetracycline. Affected animals develop exaggerated skin reactions to sunlight, particularly in unpigmented or lightly pigmented areas. Clinical signs include erythema, edema, and potentially necrosis of affected skin following sun exposure. Animals receiving chlortetracycline should be protected from intense sunlight when feasible, particularly those with significant white or unpigmented skin. The photosensitivity typically resolves after drug discontinuation, though skin damage may require time to heal.

Tooth discoloration may occur in young animals receiving chlortetracycline during the period of tooth development. Tetracyclines bind to calcium in developing teeth and bones, producing characteristic yellow-brown discoloration that becomes permanent once teeth have formed. While this effect is primarily cosmetic and does not affect tooth function, it may be a consideration in animals intended for showing or in species where dental appearance is valued. Bone deposition of tetracyclines may also occur but is generally without clinical consequence.

Superinfection with resistant organisms or fungi may occur during prolonged chlortetracycline therapy as the drug suppresses susceptible bacteria and allows resistant organisms to proliferate. Candidiasis and other fungal overgrowth may affect the gastrointestinal tract or other mucous membranes. Resistant bacterial infections may emerge during treatment, requiring modification of antimicrobial therapy. Monitoring for signs of secondary infection during treatment helps identify these complications early.

Renal and hepatic effects have been reported with tetracycline antibiotics, though significant toxicity is uncommon with chlortetracycline at therapeutic doses. Animals with pre-existing kidney or liver disease may be more susceptible to these effects. Outdated or degraded tetracycline products can cause more severe nephrotoxicity due to formation of toxic breakdown products, emphasizing the importance of using properly stored products within their expiration dates. Monitoring of renal and hepatic parameters may be advisable during prolonged therapy in high-risk animals.

Chlortetracycline is contraindicated in animals with known hypersensitivity to tetracycline antibiotics. Allergic reactions to tetracyclines, while uncommon, may manifest as skin reactions, respiratory distress, or anaphylaxis. Cross-reactivity among different tetracycline drugs should be assumed, so animals that have reacted adversely to any tetracycline should not receive chlortetracycline. Documentation of prior adverse reactions helps identify animals requiring alternative antimicrobial therapy.

Lactating dairy cattle whose milk is being sold for human consumption should not receive chlortetracycline, as no milk withdrawal time has been established for most products and residue concerns prevent approval for this population. This restriction applies regardless of the clinical indication, and alternative antimicrobials with established milk withdrawal times should be selected for lactating dairy cattle requiring treatment. Some products may have specific approvals for dry cow treatment, but milk from treated animals cannot be marketed until the specified withdrawal period following calving has elapsed.

Animals with significant renal impairment represent a relative contraindication for chlortetracycline use. The drug is partially eliminated through the kidneys, and reduced renal function may lead to drug accumulation and increased toxicity risk. Animals with known kidney disease should receive alternative antimicrobials when possible, or dose adjustments should be considered if chlortetracycline therapy is essential. Maintaining adequate hydration in renally compromised animals is particularly important if treatment proceeds.

Pregnancy during the period of fetal tooth and bone development represents a relative contraindication due to the potential for permanent tooth discoloration and skeletal effects in offspring. Chlortetracycline crosses the placenta and can affect developing fetal tissues. While the clinical significance in food animals may be limited, awareness of this potential effect is appropriate. Treatment during pregnancy should consider whether the therapeutic benefits justify the potential risks to developing offspring.

The most clinically significant interactions affecting chlortetracycline involve divalent and trivalent cations that chelate with the drug and dramatically reduce oral absorption. Calcium, magnesium, iron, aluminum, and zinc form insoluble complexes with chlortetracycline, making concurrent intake of these minerals problematic for therapeutic efficacy. High-calcium feeds, mineral supplements, and milk products should not be offered concurrently with chlortetracycline medication. Timing separation between medication and mineral supplementation helps ensure adequate drug absorption while maintaining appropriate mineral nutrition.

Antacids containing aluminum, magnesium, or calcium salts interfere with chlortetracycline absorption and should not be administered concurrently. If antacid therapy is needed in animals receiving chlortetracycline, the drugs should be separated by at least two hours to minimize the interaction. Kaolin-pectin products and other gastrointestinal adsorbents may similarly reduce chlortetracycline bioavailability through physical binding of the drug in the intestinal lumen.

Bactericidal antibiotics may interact antagonistically with chlortetracycline's bacteriostatic mechanism. Beta-lactam antibiotics including penicillins and cephalosporins require actively growing bacteria for optimal activity, and chlortetracycline's inhibition of protein synthesis may reduce bacterial growth and thereby diminish bactericidal drug efficacy. While this interaction may not always be clinically significant, concurrent use of chlortetracycline with bactericidal antibiotics should be approached thoughtfully, with consideration of whether the combination is therapeutically justified.

Ionophore antibiotics commonly used in cattle and poultry production do not have significant direct interactions with chlortetracycline, and concurrent use is common in production settings where both coccidiosis control and bacterial disease treatment are needed. However, comprehensive medication reviews should document all drugs and feed additives being administered to identify any potential interaction risks. The additive effects on gastrointestinal microflora when multiple antimicrobials are used simultaneously warrant consideration.

Human safety precautions for handling chlortetracycline include avoiding inhalation of dust from powder formulations and minimizing skin contact. Individuals with known tetracycline sensitivity should avoid handling the product. Respiratory protection may be advisable when mixing large quantities of medicated feed premix, as dust inhalation can cause irritation and potentially sensitize workers. Eye protection prevents direct contact with medication dust. Thorough handwashing after handling and before eating or drinking reduces the risk of inadvertent ingestion.

Food safety considerations require strict adherence to withdrawal times and VFD requirements. The regulatory framework governing chlortetracycline use in food animals emphasizes the importance of veterinary oversight and residue avoidance. Treated animals must be identified and tracked to ensure withdrawal periods are observed before marketing. Treatment records including VFD documentation, treatment dates, doses, and withdrawal dates must be maintained for regulatory compliance. Failure to observe withdrawal times may result in violative residues, regulatory action, and potential market access penalties.

Antimicrobial resistance is a growing concern with tetracycline antibiotics, as resistance genes are widespread among bacteria and can be transferred between organisms. Chlortetracycline should be used only when a susceptible bacterial infection is present or highly likely, and the VFD system ensures veterinary involvement in these decisions. Treatment should follow appropriate protocols designed to achieve therapeutic concentrations throughout the treatment course. Underdosing promotes resistance development by exposing bacteria to sublethal drug concentrations, while unnecessarily prolonged treatment increases selection pressure for resistant organisms.

Environmental considerations include proper disposal of unused medication and contaminated feed. Tetracyclines may persist in the environment and potentially affect soil microorganisms and aquatic ecosystems. Disposal of medicated feed and pharmaceutical waste should follow appropriate guidelines to minimize environmental release. Run-off from areas where medicated feed has been stored or fed may contain drug residues and should be managed to prevent contamination of water sources.

Product quality and storage significantly affect chlortetracycline safety and efficacy. Degraded or outdated tetracycline products may contain toxic breakdown products that cause more severe adverse effects than the parent drug. Proper storage conditions protect product integrity, and medications beyond their expiration dates should not be used. Visual inspection of products for discoloration or other evidence of degradation helps identify potentially compromised materials.

Chlortetracycline products should be stored in cool, dry conditions protected from light, heat, and moisture. Temperature extremes accelerate drug degradation, and moisture can cause caking of powder formulations and promote chemical breakdown. The storage area should be well-ventilated and free from conditions that might promote condensation. Proper storage helps maintain product potency through the labeled expiration date and prevents formation of potentially toxic degradation products.

Medicated feed containing chlortetracycline should be used within a reasonable time after manufacturing, as the drug may gradually lose potency during storage. Feed mills provide information about product stability and recommended use timeframes. Medicated feed should be stored separately from other feeds and clearly labeled to prevent accidental feeding to animals during withdrawal periods or to non-target species. Inventory management ensures that older batches are used before newer ones to minimize the time between manufacturing and consumption.

Disposal of unused chlortetracycline products, expired medications, and contaminated feed should follow appropriate environmental guidelines. The drug should not be disposed of in ways that could contaminate water supplies or allow consumption by non-target animals. Feed mills and veterinary practices may have established disposal procedures for pharmaceutical waste. Empty containers should be disposed of according to label directions, and any residual product should be removed before container disposal.

Cattle breed variations in chlortetracycline response are generally not significant, with drug efficacy and safety depending more on management factors and disease status than on genetic background. Beef breeds commonly receive chlortetracycline through medicated feed programs for respiratory disease control and anaplasmosis prevention. Dairy breeds face restrictions on chlortetracycline use during lactation but may receive the drug during the dry period or in replacement heifers with appropriate withdrawal planning. All breeds appear to respond similarly to chlortetracycline therapy when appropriate dosing is achieved.

Production type significantly influences chlortetracycline use patterns. Feedlot cattle commonly receive chlortetracycline as part of receiving programs designed to prevent respiratory disease in newly arrived animals. Cow-calf operations in anaplasmosis-endemic areas may use chlortetracycline feeding programs during the tick transmission season for disease prevention. Stocker cattle operations face disease challenges similar to feedlots and may incorporate chlortetracycline into health protocols. Dairy operations must carefully manage chlortetracycline use to avoid milk residue concerns, limiting application primarily to non-lactating animals.

Swine breed considerations are less prominent than production stage factors in determining chlortetracycline use. Modern commercial swine genetics are relatively uniform, and treatment decisions depend more on disease pressure, facility type, and production phase. Nursery pigs are frequent recipients of chlortetracycline medication for bacterial enteritis and respiratory disease. Growing and finishing pigs may receive the drug for disease treatment or control when VFD authorization is obtained. Breeding animals can be treated as indicated, with attention to any reproductive considerations and withdrawal requirements.

Poultry applications span different bird types and production purposes. Broiler chickens and meat turkeys may receive chlortetracycline for treatment or control of various bacterial infections, with attention to withdrawal times before processing. Layer operations face restrictions related to egg withdrawal, and chlortetracycline is generally not appropriate for birds in active egg production. Different poultry species may have different approved uses and withdrawal requirements, making attention to species-specific labeling important.

Within the tetracycline antibiotic class, several alternatives to chlortetracycline are available for food animal use. Oxytetracycline is perhaps the most widely used tetracycline in livestock medicine, available in injectable formulations providing convenient individual animal treatment as well as feed and water medications. The long-acting oxytetracycline formulations (LA-200, Biomycin, and others) provide extended-duration therapy from a single injection. Tetracycline hydrochloride is another option, available in both oral and injectable forms. All tetracyclines share the same general mechanism of action and spectrum of activity, though specific approved uses and formulations vary.

Non-tetracycline alternatives for the conditions commonly treated with chlortetracycline provide options when tetracyclines are contraindicated or ineffective. For respiratory infections, macrolide antibiotics (tilmicosin, tulathromycin, gamithromycin), phenicols (florfenicol), and fluoroquinolones offer alternative mechanisms of action. Sulfonamides including sulfamethazine and sulfadimethoxine provide options for certain bacterial infections. The selection among alternatives depends on the specific pathogen, susceptibility patterns, practical administration considerations, and withdrawal time requirements for the operation.

For anaplasmosis specifically, injectable oxytetracycline is commonly used for treating acute clinical cases, providing higher and more predictable drug concentrations than can be achieved with feed medication. Imidocarb dipropionate is an alternative drug class approved for anaplasmosis treatment in some countries. Prevention through tick control and herd management reduces disease pressure and complements pharmaceutical approaches to anaplasmosis management. The choice between chlortetracycline feeding programs and alternative strategies depends on endemic status, management capabilities, and regulatory framework in specific regions.